Amarex logo

Amarex Enrollment Completion Ahead of Schedule for a Diabetic Neuropathy Clinical Trial

Germantown, MD, USA (November 12, 2014) – Amarex announced today completion of enrollment for a Diabetic Neuropathy Clinical Trial. Amarex managed to enroll 128 subjects in under 5 months for this challenging indication. The sponsor's Vice President of Pharmaceutical Product Development praised Amarex on the success, noting that "this is a tremendous achievement made possible by a total team effort."

Amarex's clinical-ops team employed study design elements and Amarex's Parallel Processing approach, the company's method of optimizing efficiency through simultaneous execution of trial initiation and trial conduct activities, to maximize enrollment. Amarex's Project Manager for the trial, Anand Balasubramanian, also credited the sponsor team's effective collaboration and trust in Amarex as a contributing factor for the rapid enrollment.

About Amarex Clinical Research

Amarex is a global, full service Contract Research Organization (CRO), whose leadership team has significant expertise conducting biomedical research, and whose combined experience includes the design and conduct of several hundred clinical research projects in many therapeutic indications. Amarex provides comprehensive services in Project Management (Phase I-IV, BE/BA, PK/PD), Regulatory Affairs, FDA Applications and Submissions, Applications and Submissions to international Health Authorities, GxP Compliance Audits, Clinical Operations, Adaptive Study Designs, Statistical Analysis, Data Management and General Consulting. Amarex has taken clients’ products through the entire approval process from writing the initial product approval strategy to the marketing approval application with a growing list of approved products. Amarex is committed to cost effective, high quality clinical product development.

Amarex Contact:
Patrick J. Burke
Business Development

20201 Century Blvd., Fourth Floor
Germantown, MD 20874 USA
301 528 7000

Contact Us

Book a meeting or send us a message to talk to one of our experts.